Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets
Neve Yarak, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has entered into an engagement with Boltz, PBC (“Boltz”), an AI research lab that focuses on biomolecular foundation models and drug discovery workflows, to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins of interest to MitoCareX's pipeline.
Under this initiative, MitoCareX intends to combine two complementary and independently validated capabilities: MitoCareX’s proprietary MITOLINE® algorithm platform and Boltz’s foundation models for predicting biomolecular structure and binding affinity and designing new molecules. MitoCareX believes this integrated approach can strengthen target-specific virtual screening campaigns for challenging transporter proteins and improve hit identification.
“MITOLINE® gives us target-specific structural insight, and Boltz adds additional AI-enabled capabilities that may help us identify differentiated starting points more efficiently”, said David Palach, Chief Executive Officer of Nexentis Technologies Inc. “This approach is intended to expand our hit discovery efforts across selected transporter targets while preserving MitoCareX’s focus on building proprietary small-molecule programs.”
Using MITOLINE®, MitoCareX previously identified initial hit molecules against a selected SLC25 target and has since advanced this program through systematic medicinal chemistry optimization, culminating in the generation of an optimized hit molecule with substantially improved pharmaceutical properties - as announced in May 2026.
The initial phase of the project with Boltz is expected to focus on a selected set of SLC protein targets and virtual screening campaigns designed to identify differentiated small-molecule starting points. Subject to the results of this initial phase, the companies may expand the scope of this initiative to additional targets within MitoCareX’s broader discovery activities. MitoCareX will retain full control over its discovery programs and any small-molecule candidates it advances using this combined approach.
Boltz describes Boltz Lab as a hosted platform that combines biomolecular foundation models, managed compute, and scientist-oriented workflows, and has publicly highlighted the deployment of its models with industry partners, including a strategic collaborations with Pfizer and Takeda. BoltzMol-1, the company’s small-molecule generative pipeline is designed to model complex structures and binding affinities and support in silico screening and design of small-molecule for drug discovery programs.
MitoCareX is focused on developing novel therapies for hard-to-treat cancers and inflammatory metabolic diseases. The Company believes that combining proprietary biological and structural insight with advanced AI tools may support a differentiated discovery strategy for novel transporter-focused therapeutics.
About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer and inflammatory metabolic disease indications through the mitochondrial SLC25 protein family. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
For additional details, please visit https://nexentistech.com/
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated benefits, objectives, opportunities, potential outcomes and future activities under the initiative, as well as the parties’ expectations regarding the research, development, market opportunities, and strategic value of the initiative. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Nexentis Technologies’ and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate initiatives and collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Nexentis Technologies’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
